Mirae Asset Global Investments Co. Ltd. Acquires 5,090 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Mirae Asset Global Investments Co. Ltd. boosted its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 16.8% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 35,346 shares of the company’s stock after purchasing an additional 5,090 shares during the quarter. Mirae Asset Global Investments Co. Ltd. owned about 0.05% of IDEAYA Biosciences worth $1,258,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. China Universal Asset Management Co. Ltd. increased its position in IDEAYA Biosciences by 96.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,474 shares of the company’s stock valued at $40,000 after buying an additional 723 shares in the last quarter. Exchange Traded Concepts LLC increased its holdings in shares of IDEAYA Biosciences by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 4,806 shares of the company’s stock valued at $171,000 after acquiring an additional 1,219 shares in the last quarter. Amalgamated Bank raised its position in shares of IDEAYA Biosciences by 6.4% in the 3rd quarter. Amalgamated Bank now owns 7,205 shares of the company’s stock worth $194,000 after purchasing an additional 433 shares during the last quarter. Aigen Investment Management LP bought a new position in IDEAYA Biosciences in the 3rd quarter worth about $241,000. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its position in IDEAYA Biosciences by 6.1% during the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 9,735 shares of the company’s stock valued at $263,000 after purchasing an additional 556 shares during the last quarter. Institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Trading Up 1.2 %

IDYA opened at $37.59 on Tuesday. The company’s 50 day moving average is $43.69 and its 200 day moving average is $37.25. The company has a market cap of $2.80 billion, a price-to-earnings ratio of -19.08 and a beta of 0.80. IDEAYA Biosciences, Inc. has a 12-month low of $17.70 and a 12-month high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings results on Tuesday, February 20th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.05). The business had revenue of $3.90 million for the quarter, compared to analysts’ expectations of $8.84 million. IDEAYA Biosciences had a negative return on equity of 23.00% and a negative net margin of 483.05%. The company’s revenue was down 3.0% on a year-over-year basis. As a group, analysts predict that IDEAYA Biosciences, Inc. will post -2.26 EPS for the current fiscal year.

Insider Activity at IDEAYA Biosciences

In other news, insider Briseno Andres Ruiz sold 2,000 shares of the firm’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $46.02, for a total value of $92,040.00. Following the transaction, the insider now owns 24,531 shares of the company’s stock, valued at $1,128,916.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Yujiro S. Hata sold 23,557 shares of the company’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $45.54, for a total value of $1,072,785.78. Following the completion of the transaction, the chief executive officer now owns 677,887 shares of the company’s stock, valued at approximately $30,870,973.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Briseno Andres Ruiz sold 2,000 shares of the firm’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $46.02, for a total value of $92,040.00. Following the sale, the insider now directly owns 24,531 shares in the company, valued at $1,128,916.62. The disclosure for this sale can be found here. 5.00% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

IDYA has been the topic of several analyst reports. Capital One Financial reiterated an “overweight” rating on shares of IDEAYA Biosciences in a research note on Thursday, February 22nd. JPMorgan Chase & Co. increased their target price on IDEAYA Biosciences from $51.00 to $57.00 and gave the company an “overweight” rating in a research note on Friday, February 23rd. Royal Bank of Canada boosted their price target on IDEAYA Biosciences from $43.00 to $53.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 21st. Citigroup lifted their price objective on IDEAYA Biosciences from $40.00 to $60.00 and gave the stock a “buy” rating in a report on Thursday, March 21st. Finally, The Goldman Sachs Group upped their target price on shares of IDEAYA Biosciences from $36.00 to $53.00 and gave the company a “buy” rating in a research note on Thursday, January 25th. Thirteen research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $44.55.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.